Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases; pharmaceutical preparations designed to deliver highly targeted therapeutic modulation to patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, gastrointestinal diseases, cardiovascular and metabolic diseases, and dermatologic diseases, genitourinary diseases, and orphan diseases; protein therapeutics, namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology

Class [042]
Computer & Software Services & Scientific Services

Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating neuroendocrine tumors; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology, hepatology, laboratory medicine, clinical diagnostics, genetics and phenomics, pathology and forensics, proteomics, veterinary medicine and diagnostics, and basic research tools; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents

Mark Details

Serial Number

No 97416718

Mark Type

No Service Mark

Attorney Docket Number

44D Filed

44D Current

44E filed

44E Current

66A Filed

66A Current

Current Basis

No Basis

Legal History

Status Date	Action Taken
02^th May 2023	ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
01^st May 2023	ABANDONMENT - AFTER PUBLICATION
17^th Apr 2023	TEAS EXPRESS ABANDONMENT RECEIVED
11^th Apr 2023	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11^th Apr 2023	PUBLISHED FOR OPPOSITION
22^nd Mar 2023	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08^th Mar 2023	EXAMINERS AMENDMENT -WRITTEN
08^th Mar 2023	APPROVED FOR PUB - PRINCIPAL REGISTER
08^th Mar 2023	EXAMINER'S AMENDMENT ENTERED
08^th Mar 2023	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

INVENTING NEW HOPE

Classification Information

Class [005]Pharmaceutical Products

Class [042]Computer & Software Services & Scientific Services